首页> 美国卫生研究院文献>The Journal of Experimental Medicine >MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells
【2h】

MT1-matrix metalloproteinase directs arterial wall invasion and neointima formation by vascular smooth muscle cells

机译:MT1-基质金属蛋白酶通过血管平滑肌细胞指导动脉壁浸润和新内膜形成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

During pathologic vessel remodeling, vascular smooth muscle cells (VSMCs) embedded within the collagen-rich matrix of the artery wall mobilize uncharacterized proteolytic systems to infiltrate the subendothelial space and generate neointimal lesions. Although the VSMC-derived serine proteinases, plasminogen activator and plasminogen, the cysteine proteinases, cathepsins L, S, and K, and the matrix metalloproteinases MMP-2 and MMP-9 have each been linked to pathologic matrix-remodeling states in vitro and in vivo, the role that these or other proteinases play in allowing VSMCs to negotiate the three-dimensional (3-D) cross-linked extracellular matrix of the arterial wall remains undefined. Herein, we demonstrate that VSMCs proteolytically remodel and invade collagenous barriers independently of plasmin, cathepsins L, S, or K, MMP-2, or MMP-9. Instead, we identify the membrane-anchored matrix metalloproteinase, MT1-MMP, as the key pericellular collagenolysin that controls the ability of VSMCs to degrade and infiltrate 3-D barriers of interstitial collagen, including the arterial wall. Furthermore, genetic deletion of the proteinase affords mice with a protected status against neointimal hyperplasia and lumen narrowing in vivo. These studies suggest that therapeutic interventions designed to target MT1-MMP could prove beneficial in a range of human vascular disease states associated with the destructive remodeling of the vessel wall extracellular matrix.
机译:在病理性血管重塑过程中,嵌入血管壁富含胶原蛋白的基质内的血管平滑肌细胞(VSMC)会动员未经鉴定的蛋白水解系统以渗入内皮下空间并产生新内膜病变。尽管VSMC衍生的丝氨酸蛋白酶,纤溶酶原激活物和纤溶酶原,半胱氨酸蛋白酶,组织蛋白酶L,S和K以及基质金属蛋白酶MMP-2和MMP-9在体外和体外均与病理学基质重塑状态相关在体内,这些或其他蛋白酶在允许VSMC协商动脉壁的三维(3-D)交联细胞外基质中所起的作用仍不确定。在这里,我们证明VSMCs可以独立于纤溶酶,组织蛋白酶L,S或K,MMP-2或MMP-9进行蛋白水解重塑和侵袭胶原屏障。相反,我们将膜锚定的基质金属蛋白酶MT1-MMP确定为控制VSMCs降解和渗透间质胶原蛋白(包括动脉壁)的3-D屏障的能力的关键细胞周围胶原蛋白溶素。此外,蛋白酶的基因删除为小鼠提供了保护体内新内膜增生和体内变窄的状态。这些研究表明,针对MT1-MMP的治疗性干预措施可在一系列与血管壁细胞外基质破坏性重塑有关的人类血管疾病中证明是有益的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号